NCT05672121View on ClinicalTrials.gov

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

December 28, 2026

Study Completion Date

December 28, 2026

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

KH631

KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Trial Locations (1)

Unknown

RECRUITING

Beijing Tongren Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Chengdu Origen Biotechnology Co., Ltd.

INDUSTRY

NCT05672121 - Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Biotech Hunter | Biotech Hunter